X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GLENMARK PHARMA ALKEM LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x - 18.0 - View Chart
P/BV x 6.8 3.3 207.5% View Chart
Dividend Yield % 0.6 0.4 173.0%  

Financials

 ALKEM LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GLENMARK PHARMA
Mar-17
ALKEM LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589993 160.0%   
Low Rs1,232729 168.9%   
Sales per share (Unadj.) Rs417.5325.5 128.2%  
Earnings per share (Unadj.) Rs56.339.3 143.3%  
Cash flow per share (Unadj.) Rs64.748.7 133.0%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.2 387.7%  
Book value per share (Unadj.) Rs292.9159.2 184.0%  
Shares outstanding (eoy) m119.57282.17 42.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.6 127.7%   
Avg P/E ratio x25.121.9 114.3%  
P/CF ratio (eoy) x21.817.7 123.2%  
Price / Book Value ratio x4.85.4 89.0%  
Dividend payout %22.65.1 443.2%   
Avg Mkt Cap Rs m168,653242,991 69.4%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m9,17116,408 55.9%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m49,91591,857 54.3%  
Other income Rs m1,645374 440.3%   
Total revenues Rs m51,56192,230 55.9%   
Gross profit Rs m8,48220,367 41.6%  
Depreciation Rs m1,0062,644 38.0%   
Interest Rs m6712,373 28.3%   
Profit before tax Rs m8,45115,724 53.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,6063,827 42.0%   
Profit after tax Rs m6,73111,088 60.7%  
Gross profit margin %17.022.2 76.6%  
Effective tax rate %19.024.3 78.1%   
Net profit margin %13.512.1 111.7%  
BALANCE SHEET DATA
Current assets Rs m27,06268,746 39.4%   
Current liabilities Rs m15,32427,027 56.7%   
Net working cap to sales %23.545.4 51.8%  
Current ratio x1.82.5 69.4%  
Inventory Days Days6785 78.2%  
Debtors Days Days4196 43.2%  
Net fixed assets Rs m12,61024,132 52.3%   
Share capital Rs m239282 84.7%   
"Free" reserves Rs m34,49044,643 77.3%   
Net worth Rs m35,02744,925 78.0%   
Long term debt Rs m1,21245,363 2.7%   
Total assets Rs m54,387117,639 46.2%  
Interest coverage x13.67.6 178.4%   
Debt to equity ratio x01.0 3.4%  
Sales to assets ratio x0.90.8 117.5%   
Return on assets %13.611.4 118.9%  
Return on equity %19.224.7 77.9%  
Return on capital %24.919.1 129.8%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56356,152 11.7%   
Fx outflow Rs m3,0128,084 37.3%   
Net fx Rs m3,55248,068 7.4%   
CASH FLOW
From Operations Rs m7,2596,574 110.4%  
From Investments Rs m1,864-7,124 -26.2%  
From Financial Activity Rs m-9,2735,432 -170.7%  
Net Cashflow Rs m-1501,992 -7.5%  

Share Holding

Indian Promoters % 66.9 48.3 138.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 6.9 479.7%  
FIIs % 0.0 34.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 56,727 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK LTD  SANOFI INDIA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 145 Points Up; Sun Pharma Rallies on Strong Earnings(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is flat while the Hang Seng is up 0.7%.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


May 28, 2018 10:53 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS